Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Belinostat by Acrotech Biopharma for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Belinostat is under clinical development by Acrotech Biopharma and currently in Phase III for Anaplastic Large Cell Lymphoma (ALCL). According...
Belinostat by Acrotech Biopharma for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
Belinostat is under clinical development by Acrotech Biopharma and currently in Phase III for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According...
Belinostat by Acrotech Biopharma for Follicular Lymphoma: Likelihood of Approval
Belinostat is under clinical development by Acrotech Biopharma and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase...
Belinostat by Acrotech Biopharma for Natural Killer Cell Lymphomas: Likelihood of Approval
Belinostat is under clinical development by Acrotech Biopharma and currently in Phase III for Natural Killer Cell Lymphomas. According to...
Belinostat by Acrotech Biopharma for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Belinostat is under clinical development by Acrotech Biopharma and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
Belinostat by Acrotech Biopharma for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Belinostat is under clinical development by Acrotech Biopharma and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....